Baudax Bio, Inc. (BXRXQ)
BXRXQ Stock Price Chart
Explore Baudax Bio, Inc. interactive price chart. Choose custom timeframes to analyze BXRXQ price movements and trends.
BXRXQ Company Profile
Discover essential business fundamentals and corporate details for Baudax Bio, Inc. (BXRXQ) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
21 Feb 2024
Employees
9.00
Website
https://www.baudaxbio.comCEO
Geraldine A. Henwood
Description
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania. On February 22, 2024, Baudax Bio, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of Pennsylvania.
BXRXQ Financial Timeline
Browse a chronological timeline of Baudax Bio, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 11 Feb 2025
Earnings released on 15 Nov 2024
Earnings released on 16 Aug 2024
Earnings released on 16 May 2024
Earnings released on 14 Feb 2024
Earnings released on 20 Nov 2023
Earnings released on 16 Aug 2023
EPS came in at -$1.49 surpassing the estimated -$2.04 by +26.96%.
Earnings released on 12 May 2023
EPS came in at $4.91 falling short of the estimated $5.75 by -14.61%.
Earnings released on 23 Feb 2023
EPS came in at -$4.25 surpassing the estimated -$9.76 by +56.48%, while revenue for the quarter reached $310.00K .
Stock split effective on 1 Dec 2022
Shares were split 1 : 40 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 8 Nov 2022
EPS came in at -$15.71 surpassing the estimated -$21.20 by +25.89%, while revenue for the quarter reached $238.00K , missing expectations by -75.34%.
Earnings released on 11 Aug 2022
EPS came in at -$27.67 surpassing the estimated -$50.80 by +45.53%, while revenue for the quarter reached $300.00K , missing expectations by -61.19%.
Stock split effective on 16 Feb 2022
Shares were split 1 : 35 , changing the number of shares outstanding and the price per share accordingly.
BXRXQ Stock Performance
Access detailed BXRXQ performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.